NCT05431153 - A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 10, 2022

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions

Healthy

Interventions

DRUG

Single dose of PF-07104091 as Tablet Formulation A (Treatment A)

A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

DRUG

Single dose of PF-07104091 as Tablet Formulation B (Treatment B)

A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

DRUG

Single dose of PF-07104091 as Tablet Formulation C (Treatment C)

A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

DRUG

Single dose of PF-07104091 as Tablet Formulation D (Treatment D)

A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.

DRUG

Single dose of PF-07104091 as Tablet Formulation C (Treatment E)

A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.

Trial Locations (1)

New Haven Clinical Research Unit, New Haven